Concepedia

Todd Eary

TE

Statistics

Publications

3

Citations

95

H-Index

3

Active since

2005

Affiliations

Loxo Oncology at Lilly (United States)(Current)

Todd Eary is an author at Loxo Oncology at Lilly (United States) specializing in pharmacology, cancer pharmacology, and medicine.

Publications per year

2005–2018

3

Publications

3

LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors

Barbara J. Brandhuber, Eliana B Gómez, Steven G. Smith et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 62 citations

, , +10

OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases

Vamsidhar Velcheti, Todd M. Bauer, Vivek Subbiah et al. · Journal of Thoracic Oncology · 2017 · 21 citations · Full text

, , +14

Synthesis of spirolactams and spiropiperidines as CCR4 receptor antagonists

Joshua D. Hansen, Bradley J. Newhouse, Shelley Allen et al. · Tetrahedron Letters · 2005 · 12 citations

, , +12

1–3 of 3